Minerva Surgical (UTRS – Research Report) received a Sell rating and price target from J.P. Morgan analyst Robbie Marcus yesterday. The company’s shares closed yesterday at $1.98.
According to TipRanks, Marcus is a 4-star analyst with an average return of 9.6% and a 54.36% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Baxter International, Intuitive Surgical, and Minerva Surgical.
Currently, the analyst consensus on Minerva Surgical is a Hold with an average price target of $5.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.37 and a one-year low of $1.61. Currently, Minerva Surgical has an average volume of 37.61K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Minerva Surgical Inc is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
Read More on UTRS:
- J.P. Morgan downgrades Invitae (NVTA) to a Sell
- J.P. Morgan Sticks to Its Hold Rating for Charter Hall Social Infrastructure REIT (FKKEF)
- Analysts Have Conflicting Sentiments on These Financial Companies: Alexandria Equities (ARE), Regency Centers (REG) and ASX Limited (OtherASXFF)
- GPT Group (GPTGF) Gets a Sell from J.P. Morgan
- J.P. Morgan Reaffirms Their Buy Rating on Insurance Australia Group Limited (IAUGF)
